Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +4.50p +0.36% 1,240.00p 1,239.50p 1,240.00p 1,242.00p 1,231.50p 1,237.00p 555,319 09:59:31
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,781.0 860.0 71.3 19.7 10,851.45

Smith & Nephew Share Discussion Threads

Showing 801 to 825 of 825 messages
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
DateSubjectAuthorDiscuss
22/1/2018
10:20
Strykers full results are on Jan 30, the next few weeks will be interesting. Stryker provides 2017 preliminary net sales results By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were: Preliminary Fourth Quarter Highlights Net sales grew 10.0% to $3.5 billion (8.7% constant currency) Orthopaedics 8.1 % or 6.8 % constant currency MedSurg 10.9 % or 9.8 % constant currency Neurotechnology and Spine 11.5 % or 10.3 % constant currency Preliminary Full Year Highlights Net sales grew 9.9% to $12.4 billion (9.8% constant currency) Orthopaedics 6.6 % or 6.5 % constant currency MedSurg 13.6 % or 13.4 % constant currency Neurotechnology and Spine 8.2 % or 8.3 % constant currency Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year. Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year. "We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."
basil brush1
22/1/2018
10:16
Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.
basil brush1
21/1/2018
12:42
Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.
its the oxman
19/1/2018
08:39
imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.
basil brush1
18/1/2018
16:25
Could have further to fall (imo) 11-Oct-17Citigroup Sell Now 1,233.50 Then 1,359.00 New target 1,160.00
pugugly
17/1/2018
11:18
these were 1440 less than 3 months back. are the powers than be managing the price down so to get a bid in at not much higher than the October highs?
basil brush1
16/1/2018
20:07
As a quality operator surely SN will get some bid speculation this year. Must be so tempting now it's slipped back to 1250p.
its the oxman
05/1/2018
12:29
nice to finally see a rally. S&N has underperformed stryker by 75% over two years in dollar terms. S&N ADRs are unchanged while stryker has gone up by 75%. unbelievable.
basil brush1
02/1/2018
21:54
this is a real dog stock. having tracked stryker closely for decades, this has incredibly under-performed by a massive 75% in the last two years. three years ago stryker was only slightly bigger than S&N, now it is four times the size.
basil brush1
15/12/2017
14:05
Anyone know why these are trading at such a big discount to Stryker? Is it because SN does not have enough debt on board? I have SN on a PE ratio of 18 from Google Finance, with SYK at 35.
basil brush1
13/12/2017
14:58
these shares seem to have dodgy knees.... anyone know what happened with Elliot Advisors? http://www.telegraph.co.uk/business/2017/11/03/smith-nephew-boss-defends-strategy-elliott-circles/
basil brush1
13/11/2017
12:15
Dodgy knees and hips aren't going away - keep buying.
its the oxman
03/11/2017
16:26
Looking for a safe home for some funds. Nice chart, reasonable valuation, defensive sector all looks nice. Update this morning states "Full year outlook at the lower end of guidance range" yet the shares are up over 2.0%. Can only assume the market is impressed by the CEO's buy which isn't particularly large for someone running a multi-billion pound company. Think I'll keep an eye on broker forecasts for now.
quant_investor
27/10/2017
09:20
SN. Smith @Nephew..reports on 3rd of November and im expecting share price to chase upwards to that date. Gap up at open on verge of 5 year breakout.
3rd eye
13/10/2017
11:58
S @ N Smith @ Nephew.............. https://www.bloomberg.com/news/articles/2017-10-10/singer-s-elliott-is-said-to-build-a-stake-in-smith-nephew
3rd eye
12/10/2017
11:58
inference was they have only got 0.5% but as you say nobody knows and it is definitely under 3% disclosable. if I was them, I would not be happy if they were building a stake.
edwardt
12/10/2017
07:01
Lot of discussion on FTs Alphaville yesterday.S&N figures coming up Nov 3rd,could be weak given hurricanes that have interrupted Florida hip replacement market.Doing various calculations,a target price of £17-80 is mentioned,this in the event of a bid I presume.Natter about breaking up Smith and Nephew.Johnson&Johnson and Stryker mentioned as perennial takeover possibles.Just what stake Eliott have taken remains unknown for now.
steeplejack
11/10/2017
12:58
perhaps sell it to vest his options before he goes - I know that is what I would be thinking :)
edwardt
11/10/2017
11:18
He's not going til the end of 2018 by which time he'll be in his 60th year.Happy retirement.
steeplejack
11/10/2017
10:11
stryker are the obvious home for it - not sure where they are at but recall they put in place a large buy back programme in 15 instead of bidding for sn. their balance sheet is very solid so they could easily make a juicy bid imo. lets see but funny how the ceo left abruptly....
edwardt
11/10/2017
09:10
Year's high.
steeplejack
11/10/2017
08:55
Elliott are renowned for shaking things up - the spat at BHP is illustrative of this.
edwardt
11/10/2017
08:14
Lets hope there might be something in it. Perennial bid candidate though - that's why I bought and hold. One day, Rodney.
broadwood
11/10/2017
08:11
FT reports this morning that the stock rose on news that Eliott Management had built a stake.Nothing more than that at the moment
steeplejack
11/10/2017
07:46
Elliot rumoured to have built a stake - can not see an rns to that effect - anyone know more?
edwardt
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180123 10:14:38